Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
TD Cowen on Compass Pathways (CMPS) FDA Grant: 'meaningful positive and expected in light of last Saturday’s Executive Order'
April 24, 2026 3:41 PM EDTTD Cowen analyst Ritu Baral reiterated a Buy rating and $29.00 price target on Compass Pathways (NASDAQ: CMPS)
The analyst comments "Our View: We view the CPNV as a meaningful positive and expected in light of last Saturdays Executive Order accelerating development and access for psychedelicbased... More
Oppenheimer on Compass Pathways (CMPS) FDA Grant: 'reinforcing our conviction considering the earlier launch timeline for COMP360 in TRD'
April 24, 2026 1:24 PM EDTOppenheimer analyst Francois Brisebois reiterated an Outperform rating and $20.00 price target on Compass Pathways (NASDAQ: CMPS).
The analyst comments "We view FDA granting a CNPV with agreement on NDA rolling review as reinforcing our conviction considering the earlier launch timeline for COMP360 (psilocybin)... More
Morgan Stanley on Compass Pathways (CMPS): 'we view today’s update as incrementally encouraging'
April 24, 2026 1:06 PM EDTMorgan Stanley analyst Judah C. Frommer reiterated an Overweight rating and $16.00 price target on Compass Pathways (NASDAQ: CMPS).
The analyst comments "The FDA announced this morning "a series of regulatory actions to support the development of serotonin-2A agonists and related products" (see here) following its Executive Order from earlier this week (see here). While the EO focused on accelerating access for serious mental illness broadly, todays update centers on the... More
